A Pilot Study to evaLuate the Role of High-dose rAnbizumab (2.0mg) in the Management of AMD in Patients With perSistent/recurrenT Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) (LAST)

This study has been completed.
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
Vitreous -Retina- Macula Consultants of New York
ClinicalTrials.gov Identifier:
NCT01115556
First received: April 30, 2010
Last updated: December 30, 2015
Last verified: December 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: January 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)